Nilotinib
Anticancer Drug (Aminopyrimidine Derivative)
Blood cancer (Chronic myeloid leukaemia)
Why Partner with Pinnacle Life Science
Regulatory Compliance
Manufactured under WHO-GMP compliant processes at our US FDA approved facility in Baddi, Himachal Pradesh.
Consistent Quality
Rigorous quality control at every stage ensures reliable purity and potency across every batch produced.
Global Reach
Trusted by pharmaceutical partners and distributors across 90+ countries worldwide.
Mechanism of Action
Nilotinib is a selective tyrosine kinase inhibitor that targets BCR-ABL kinase, c-KIT and platelet derived growth factor receptor (PDGFR); it does not have activity against the SRC family. Nilotinib inhibits BCR-ABL mediated proliferation of leukemic cell lines by binding to the ATP-binding site of BCR-ABL and inhibiting tyrosine kinase activity.
Contact Us
